Results 141 to 150 of about 72,428 (200)

Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management

MedComm, Volume 6, Issue 11, November 2025.
Thyroid cancer risk is influenced by both genetic and modifiable factors, including mutations, radiation exposure, lifestyle, and pre‐existing benign conditions. Diagnosis involves physical exams, ultrasound, scintigraphy, laboratory tests, and fine‐needle aspiration biopsy (FNAB).
Yu‐Dong Li, Qing‐Yao Ye, Yan‐Xing Chen, Xia‐Rong Hu   +3 more
wiley   +1 more source

Niclosamide prodrug enhances oral bioavailability and efficacy against hepatocellular carcinoma by targeting vasorin‐TGFβ signalling

British Journal of Pharmacology, Volume 182, Issue 22, Page 5517-5535, November 2025.
Abstract Background and Purpose Hepatocellular carcinoma (HCC), the third leading cause of cancer‐related deaths worldwide, has limited treatment options and high mortality rate. We previously used a bioinformatics approach to identify niclosamide (NIC) as a promising repurposed drug candidate for HCC.
Mingdian Tan, Wei Ye, Yi Liu, Xiaowu Chen, Lakshmi Huttad, Mei‐Sze Chua, Samuel So   +6 more
wiley   +1 more source

BH4 Oxidation‐Derived H2O2 Activates ERK1/2 Signaling via B‐Raf in Rat Dorsal Root Ganglion Neurons

Journal of Neurochemistry, Volume 169, Issue 11, November 2025.
Tetrahydrobiopterin (BH4) is linked to various pain conditions, but targeting its synthesis in vivo is prone to side effects. We now characterized a so far unknown mechanism of BH4‐induced signaling in sensory neurons. In rat dorsal root ganglion (DRG) neurons, we identified neither BH4 nor its oxidation product, BH2, but the byproduct H2O2 to induce ...
Milad Mohammadi, Maike Siobal, Jörg Isensee, Philipp N. Ostermann, Tim Hucho   +4 more
wiley   +1 more source

The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review. [PDF]

Health Sci Rep
Shamahmood MN, Miri A, Mezginejad F.
europepmc   +1 more source

Targeting MED8 enhances sorafenib sensitivity in hepatocellular carcinoma by disrupting epithelial-mesenchymal transition mechanisms. [PDF]

J Enzyme Inhib Med Chem
Li M, You X, Yuan T, He J, Xu Z, Liang S, Mao L, Jin A, Zhou X, Yi B, Li J, Tu Q.   +11 more
europepmc   +1 more source

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma. [PDF]

Sci Rep
Qiu Q, Yin H, Zhang L, Xu W, Zhu S, Zhang Q, Zhao M, Qian Y, Ruan Y, Zhang H, Wu Z, Liu J, Ke J, Dai Y, Wang W, Sun W, Gao Y, Xu H.   +17 more
europepmc   +1 more source

The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery. [PDF]

Sci Rep
Lu H, Liang B, Xia X, Kan X, Zheng C.
europepmc   +1 more source

Assessment of the main signaling pathways involved in the combined therapy of hepatocellular carcinoma using Sorafenib and NK cells in xenograft mice model. [PDF]

Toxicol Rep
Hosseinzadeh F, Komeili Movahhed T, Dolati M, Kheirkhah AH, Beheshtizadeh N, Verdi J.   +5 more
europepmc   +1 more source

The advantages and challenges of sorafenib combination therapy: Drug resistance, toxicity and future directions (Review). [PDF]

Oncol Lett
Wei M, Cao Z, Dong L, Wang W, Wei M, Ji L, Duan L, Sun H, Zheng M.   +8 more
europepmc   +1 more source

Immune system development-related signature predicts prognosis and sorafenib-treatment resistance of hepatocellular carcinoma by intergrating machine learning and single-cell analyses. [PDF]

Sci Rep
Wu S, Chen X, Fang H, Zhong Y, Huang Q, Hong L, Shao L, Wang L, Wu J.   +8 more
europepmc   +1 more source